Importantly, nintedanib downregulated critical profibrotic mediators including TGF-β1 and Mer tyrosine kinase (MerTK)—a receptor implicated in pulmonary fibrosis pathogenesis [81]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.